Reston, VA (October 2, 2026)— New research has been published ahead-of-print by The Journal of Nuclear Medicine ( JNM ). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
Summaries of the newly published research articles are provided below.
GD2-Targeted PET Detects More Neuroblastoma Metastases Than MIBG SPECT
A preliminary study compared GD2-targeted 64 Cu-NOTA-ch14.18/CHO PET with standard 123 I-MIBG SPECT in five patients with neuroblastoma. Both imaging methods detected lesions in every patient, while 64 Cu-GD2 PET identified additional metastatic lesions in patients with multiple metastases, resulting in higher disease scores.
Open-Source PET AI Improves Automated Tumor Segmentation
A new open-source pipeline known as LION automatically segments tumors on 18 F-FDG and PSMA-targeted PET/CT. In a multicenter study of more than 7,000 scans, including 19 disease types, incorporating organ context improved segmentation accuracy. Greater tumor spatial diversity in training data was also strongly associated with better performance across different diseases and scanners.
PET Imaging Offers a New Way to Visualize 225 Ac Therapy
A new imaging technique called time-of-flight cascade γ-ray imaging (TOF-CGI) enabled visualization of the therapeutic radionuclide 225 Ac using a PET scanner. Testing with vials and clinical-size phantoms showed improved detection efficiency and signal-to-noise compared with SPECT, while a patient study demonstrated imaging of 225 Ac-PSMA-617 in a known prostate tumor.
New PET Approach Shows Promise for Imaging HER2-Positive Tumors
Researchers evaluated the 140 Nd/ 140 Pr PET generator system using HER2-targeted trastuzumab in preclinical models. The DOTA-based radiotracer remained stable for seven days and showed substantially greater uptake in HER2-positive tumors than HER2-negative tumors. PET/CT imaging demonstrated sustained tumor accumulation, supporting further investigation of this approach for antibody-based theranostic imaging.
Visit the JNM website for the latest research, follow our Twitter and Facebook pages @JournalofNucMed, and join us on LinkedIn .
###
Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or rmaxey@snmmi.org .
About JNM and the Society of Nuclear Medicine and Molecular Imaging
The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed more than 90 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org .
JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit www.snmmi.org .
Journal of Nuclear Medicine